Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 50%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Adverse events: all grades · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.99 [0.74, 1.31]
1 study · 243 participants
Low

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
OR 4
3 participants
GRADE not reported